Anti-dislocation piece and needleless injector

Abstract

A displacement prevention material for suppressing displacement between a target region of an eyeball that is an injection target and a syringe that ejects an injection target substance from an ejection port toward the target region, the displacement prevention material being provided with: a base body that is provided on the injection port; an injection part disposed around an axis along the injection direction of the injection target substance so as to surround the injection part; and a concavo-convex portion provided on the target region side of the base body.

Description

Technical Field

[0001] This invention relates to anti-misalignment components and needle-free injectors. Background Technology

[0002] Patent document 1 discloses a device for delivering a drug into the eye, comprising a housing, at least one nozzle in a portion of the housing, a drug supply source within the housing, and an energy source that provides pressure to expel the drug through the at least one nozzle out of the housing.

[0003] Existing technical documents

[0004] Patent documents

[0005] Patent Document 1: Japanese Patent Application Publication No. 2007-044529 Summary of the Invention

[0006] The problem that the invention aims to solve

[0007] The device in Patent Document 1 lacks a feature that prevents the injection position from shifting due to patient movement, for example, during drug injection. Therefore, a problem arises where the injection position shifts during drug injection, potentially causing lacerations.

[0008] The technology disclosed herein was made in view of the above-mentioned actual situation, and its purpose is to provide a way to suppress the deviation of the syringe relative to the target area of ​​the eyeball.

[0009] Solution for solving the problem

[0010] To address the aforementioned problems, the present disclosure discloses an anti-misalignment device for suppressing the misalignment between the syringe and the target region of the eyeball, which is the recipient of the injection, wherein the syringe ejects the target substance from the ejection portion into the target region.

[0011] The anti-misalignment component includes:

[0012] The matrix is ​​arranged around an axis along the ejection direction of the injected target material, in a manner that surrounds the periphery of the ejection portion; and

[0013] The protrusions and recesses are provided on the object region side of the substrate.

[0014] In the aforementioned anti-misalignment component, it could also be,

[0015] The syringe is a syringe that injects the target substance into the target area by ejecting the target substance from the ejection port, which is the ejection part, without passing through the injection needle.

[0016] In the aforementioned anti-misalignment component, it could also be,

[0017] The needle-free injector includes a receiving portion having a receiving space for receiving the injected target substance, and an injection port for ejecting the injected target substance into the target area.

[0018] The substrate is assembled into the receiving portion of the needle-free injector.

[0019] In the aforementioned anti-misalignment component, it could also be,

[0020] The needle-free injector comprises: a receiving portion having a receiving space for receiving the target substance and an ejection port for ejecting the target substance into the target area; and a retaining portion for retaining the receiving portion.

[0021] The substrate is fitted to the retaining part of the needleless injector.

[0022] In the aforementioned anti-misalignment component, it could also be,

[0023] The ejection portion of the syringe is equipped with an injection needle.

[0024] The substrate is positioned around the axis surrounding the injection needle.

[0025] In the aforementioned anti-misalignment component, it could also be,

[0026] The concave and convex portion has multiple protrusions around the axis, and the contact surface of each protrusion that abuts against the eyeball is formed along a predetermined curved surface corresponding to the eyeball.

[0027] To address the aforementioned problems, the needle-free injector disclosed herein is an injector that ejects a target substance from its ejection portion into the target region of the eyeball, the recipient of the injection. The injector comprises:

[0028] The receiving portion has a receiving space for receiving the injected target substance, and has an ejection portion for ejecting the injected target substance into the target area; and

[0029] An anti-misalignment component is used to suppress the displacement of the needleless injector relative to the target area.

[0030] The anti-misalignment component includes:

[0031] The matrix is ​​arranged around an axis along the ejection direction of the injected target material, in a manner that surrounds the periphery of the ejection portion; and

[0032] The concave and convex portions are provided on the surface of the substrate opposite to the object region.

[0033] Alternatively, the syringe can be a needleless syringe that injects the target substance into the target area by ejecting the target substance from an ejection port, which serves as the ejection part, without passing through an injection needle.

[0034] Alternatively, in the syringe, the base may be assembled into the receiving portion of the needleless syringe.

[0035] In the syringe, it could also be,

[0036] The syringe also includes a retaining part for holding the receiving portion.

[0037] The substrate is fitted to the retaining part of the needleless injector.

[0038] In the syringe, it could also be,

[0039] The ejection section is equipped with an injection needle.

[0040] The substrate is positioned around the axis surrounding the injection needle.

[0041] In the syringe, the concave and convex portions may have multiple protrusions around the axis, and the contact surface of each protrusion that abuts against the eyeball is formed along a predetermined curved surface corresponding to the eyeball.

[0042] Invention Effects

[0043] According to this disclosure, it is possible to suppress the deviation of the syringe relative to the target area of ​​the eyeball. Attached Figure Description

[0044] Figure 1 This is a schematic diagram showing the appearance of a syringe.

[0045] Figure 2 This is a first sectional view of the syringe; its section will be described later. Figure 4 AA section in the middle.

[0046] Figure 3 This is a second sectional view of the syringe, the section of which will be described later. Figure 4 The BB section is orthogonal to the AA section.

[0047] Figure 4 This is a diagram showing the structure that makes up the casing of a syringe.

[0048] Figure 5 This is a diagram showing the general structure of the syringe components.

[0049] Figure 6 It is a cross-sectional view showing the approximate structure of the container.

[0050] Figure 7It is a diagram showing the approximate structure of the container.

[0051] Figure 8 This is a diagram showing the general structure of the anti-misalignment component, viewed from a direction orthogonal to the ejection direction of the syringe (side view).

[0052] Figure 9 yes Figure 8 A sectional view.

[0053] Figure 10 This is a diagram showing the anti-misalignment component viewed from the top side.

[0054] Figure 11 This is a diagram showing the anti-misalignment component viewed from the base side.

[0055] Figure 12 It is a three-dimensional diagram showing the general structure of the anti-misalignment component.

[0056] Figure 13 This is a schematic diagram showing the positional relationship between the contact surface of the anti-misalignment component and the injection port.

[0057] Figure 14 This is a diagram showing the schematic configuration of the anti-misalignment component and container according to the second embodiment.

[0058] Figure 15 This is a diagram used to illustrate the positional relationship between the container and the container holder in the second embodiment.

[0059] Figure 16 This is a cross-sectional view showing the schematic configuration of the anti-misalignment component and container according to the third embodiment.

[0060] Figure 17 This is a diagram showing the anti-misalignment component of the third embodiment as viewed from the top side.

[0061] Figure 18 This is a schematic diagram of the syringe according to the fourth embodiment.

[0062] Figure 19 This is a diagram showing the top side of the anti-misalignment member according to the fourth embodiment.

[0063] Figure 20 This is a diagram showing the base end side of the anti-misalignment member according to the fourth embodiment.

[0064] Figure 21 This is a schematic diagram of the syringe according to the fifth embodiment.

[0065] Figure 22 It is a diagram showing a cross-section of the tip side of the syringe. Detailed Implementation

[0066] <First Implementation>

[0067] Hereinafter, with reference to the accompanying drawings, the needleless injector (hereinafter referred to as "injector") 1 of the embodiment disclosed in this application will be described. The injector 1 is a needleless injector that uses the combustion energy of gunpowder to eject an ejaculate liquid equivalent to the target substance of this application into the target area. That is, it is a device that injects by ejecting an ejaculate liquid into the target area without using an injection needle.

[0068] It should be noted that the various components and combinations thereof in each embodiment are merely examples, and appropriate additions, omissions, substitutions, and other modifications to the components can be made without departing from the spirit of this application. This application is not limited to the embodiments, but only to the claims. In this embodiment, "tip side" and "base side" are used as terms in the syringe 1 to indicate their relative positional relationship in the longitudinal direction. The "tip side" refers to the position near the tip of the syringe 1 (described later), i.e., near the injection port 77, and the "base side" refers to the direction of the syringe 1 in the longitudinal direction opposite to the "tip side," i.e., the syringe assembly 10 (see the following description). Figure 5 The direction of the igniter 22 side in the ).

[0069] <Composition of Syringe 1>

[0070] Here, Figure 1 This is a schematic diagram showing the appearance of syringe 1. Figure 2 This is a first sectional view of syringe 1, the section of which will be described later. Figure 4 Section AA in the image. Furthermore... Figure 3 This is a second sectional view of syringe 1, the section of which will be described later. Figure 4 The BB section is orthogonal to the AA section. Figure 4 This is a diagram showing the structure of the housing 2 that makes up the syringe 1. Figure 5 This is a diagram showing the schematic configuration of the syringe assembly 10. The syringe 1 is formed by assembling the syringe assembly 10 into the housing 2. Furthermore, a power cable 3 for supplying driving current to the igniter 22 within the syringe assembly 10 is connected to the housing 2. Figure 1 ).

[0071] It should be noted that, in the subsequent description of this application, the extruded liquid injected into the target area using syringe 1 is formed by containing a specified substance in a liquid medium that performs the desired effect or function of the target area. In this extruded liquid, the specified substance may be dissolved in the liquid medium, or it may be mixed but not dissolved.

[0072] Examples of substances included in the ejaculate include biologically derived substances that can be ejected onto the target area of ​​a living organism, and substances that exhibit the desired physiological activity. Examples of biologically derived substances include DNA, RNA, nucleic acids, antibodies, and cells. Examples of substances exhibiting physiological activity include drugs composed of low molecular weight molecules, proteins, peptides, etc., vaccines, inorganic substances such as metal particles used in thermotherapy and radiotherapy, and substances containing carriers with various pharmacological / therapeutic effects. Furthermore, the liquid serving as the medium for the ejaculate can be any substance suitable for delivering these specified substances into the target area, regardless of its aqueous or oily nature. Moreover, the viscosity of the liquid serving as the medium is not particularly limited, as long as the specified substances can be ejected through syringe 1.

[0073] In syringe 1, syringe assembly 10 is configured to be removable from and detachable from housing 2. During the preparation phase before syringe 1 is operational, fluid is introduced into the receiving space 75 (see reference 2) formed between the container (receiving portion) 70 and the plunger 80 included in syringe assembly 10. Figure 5 The syringe assembly 10 is a unit that is replaced each time an ejaculate is dispensed. Details about the syringe assembly 10 will be described later.

[0074] On the other hand, the housing 2 has a handle 2a for the user to grip and use the syringe 1, and is provided with multiple switches for operating the syringe 1 to eject the ejaculate fluid. It should be noted that the syringe 1 is configured so that the user can grip and operate it with one hand. Here, based on... Figure 4 The casing 2 will be described. Figure 4 middle, Figure 4 (a) indicates the appearance of housing 2 as viewed from the front. Figure 4 (b) shows the appearance of housing 2 as viewed from the side. Figure 4 (c) indicates the appearance of housing 2 as viewed from the rear. Figure 4 (d) indicates the appearance of housing 2 as viewed from above. Here, "front" refers to the part located at the farthest point from the user when the user grips housing 2. Figure 4 In (b), the part located on the left side, and "behind" refers to the part located closer to the user, in contrast. Figure 4 In (b), it is located on the right side. Therefore, when the user holds the housing 2 with one hand, their fingertips are hooked in front of the housing 2, which is the distal side, and their wrist is close to the rear of the housing 2, which is the proximal side. In addition, "above" refers to the part on the base side of the syringe 1.

[0075] Considering the user's grip, a handle portion 2a is provided at the front of the housing 2 to facilitate hooking by the user's fingertips. Multiple indentations are formed in the handle portion 2a to improve the hooking experience for the user's fingertips. Furthermore, to further stabilize the user's grip on the housing, the front side of the handle portion 2a has a gently sloping contour with raised and recessed areas (see reference). Figure 4 (b) makes it easy for the user's index and middle fingers to hook.

[0076] Furthermore, the housing 2 is equipped with two operating switches for operating the syringe 1: a first switch 5 and a second switch 6. The first switch 5 and the second switch 6 are connected to a control unit (not shown) such as a microcomputer. This control unit controls the supply of ignition current to the igniter 22 based on signals from each switch, thereby controlling the operation of the syringe 1. Here, the first switch 5 is a sliding switch located at the rear of the housing 2, and its sliding direction is the vertical direction of the housing 2 (the direction connecting the top and bottom ends). The first switch 5 is always subjected to upward force. By continuously sliding the first switch 5 downward (towards the top end) against its applied force for a certain period of time, the user can bring the syringe 1 to a standby state. This standby state refers to the state in which preparation for ejecting the ejaculate liquid is completed in the syringe 1, and it is also the state in which ejection will be performed if the user performs additional operations.

[0077] Next, the second switch 6 is a push-button switch located on the inclined surface 2b above the housing 2, which the user can press inwards towards the housing 2. When the syringe 1 is in a standby state due to the operation of the first switch 5, pressing the second switch 6 configures the control unit to supply ignition current to the igniter 22. Furthermore, a connector 4 for connecting the power cable 3 is provided in front of the inclined surface 2b above the housing 2. In this embodiment, the connector 4 is a USB (Universal Serial Bus) connector, and the power cable 3 is designed to be detachable from the housing 2.

[0078] It should be noted that, as described above, in this embodiment, power for operating the igniter 22 is supplied from the outside via the power cable 3. However, alternatively, a battery for supplying this power can be installed inside the housing 2. In this case, as long as there is remaining power in the battery, the housing 2 can be reused repeatedly while replacing the syringe assembly 10. Furthermore, when the battery runs out of power, it can simply be replaced.

[0079] Here, Figure 5 The schematic configuration of syringe assembly 10 is shown in the figure. (As shown) Figure 2 and Figure 3As shown, the syringe assembly 10 forms the syringe 1 by being assembled into the housing 2. Specifically, the syringe assembly 10 is an assembly including an actuator (drive unit) 20, an accessory 30, an anti-misalignment component 50, a container 70, and a plunger 80. The assembly of the syringe assembly 10 will be described later.

[0080] Regarding the actuator 20, its main body 21 is formed in a cylindrical shape. The main body 21 has a central portion 21a at its center, a top portion 21b at its top end, and a base portion 21c at its base end. The internal spaces of the top portion 21b, the central portion 21a, and the base portion 21c are interconnected in the main body 21, and an opening 27 is provided at the top end of the top portion 21b. Here, an igniter 22 is mounted at the base portion 21c of the main body 21. This igniter 22 is an electric igniter that causes the initiating explosive to burn and generate ejection energy. The igniter 22 has an ignition lead 22b that is supplied with ignition current from the outside. This ignition lead 22b is connected to a socket 7 on the housing 2 side when the syringe assembly 10 is assembled with the housing 2. Furthermore, the assembly state of the igniter 22 relative to the main body 21 is determined such that the combustion products generated by the operation of the igniter 22 are released toward the central portion 21a of the main body 21. That is, the igniter 22 is mounted on the base end 21c of the main body 21 in such a way that the combustion product release surface 22c faces the central part 21a.

[0081] Here, the combustion energy of the initiating explosive used in the igniter 22 becomes the energy required to propel the injector 1 to the target area. It should be noted that the following explosives, or combinations thereof, are preferably used as the initiating explosive: zirconium and potassium perchlorate explosives (ZPP), titanium hydride and potassium perchlorate explosives (THPP), titanium and potassium perchlorate explosives (TiPP), aluminum and potassium perchlorate explosives (APP), aluminum and bismuth oxide explosives (ABO), aluminum and molybdenum oxide explosives (AMO), aluminum and copper oxide explosives (ACO), and aluminum and iron oxide explosives (AFO). These explosives generate high-temperature, high-pressure plasma upon immediate combustion after ignition, but if the combustion products condense at room temperature, they contain no gaseous components, thus exhibiting a characteristic of a rapid pressure drop. It should be noted that explosives other than these can also be used as the initiating explosive, provided that a suitable injectable liquid can be ejected.

[0082] The main body 21 is a cylindrical component, and the internal space of the central portion 21a is configured as a combustion chamber 20a. Furthermore, an external thread 26 is formed on a portion of the outer surface of the central portion 21a. The external thread 26 is configured to engage with the internal thread 32 of the accessory 30 (described later), and the effective lengths of the external thread 26 and the internal thread 32 are determined to ensure the required engagement force between them. Additionally, the internal space of the top portion 21b adjacent to the central portion 21a is formed in a cylindrical shape and is configured to allow the piston 40 to slide within this internal space.

[0083] Furthermore, when the igniter 22 is activated, combustion products are released into the combustion chamber 20a, and as the pressure in the combustion chamber 20a rises, the piston 40 slides towards its tip under this pressure. That is, the actuator 20 has a mechanism that uses the igniter 22 as the working source and the piston 40 as the output.

[0084] like Figure 5 As shown, Annex 30 is a component used for assembling the actuator 20, plunger 80, and container 70. The body 31 of Annex 30 can be made of resins such as known nylon 6-12, polyarylate, polybutylene terephthalate, polyphenylene sulfide, or liquid crystal polymers. Furthermore, these resins may contain fillers such as glass fibers or glass fillers; polybutylene terephthalate may contain 20% to 80% by mass of glass fibers; polyphenylene sulfide may contain 20% to 80% by mass of glass fibers; and liquid crystal polymers may contain 20% to 80% by mass of minerals. It should be noted that the material of Annex 30 is not limited to resin; it can also be metal or ceramic.

[0085] like Figure 5 As shown, the actuator 20 is disposed in the internal space of the main body 31 from the base end side to the center. Furthermore, the base end portion 21c of the actuator 20 is approximately located in the base end side region of the internal space where the actuator 20 is disposed, and the central portion 21a and the top portion 21b of the actuator 20 are approximately located in the top end side region with a diameter smaller than that of the base end side. In addition, an internal thread portion 32 is disposed on the inner wall surface of the main body 31, and the internal thread portion 32 is formed to engage with the external thread portion 26 provided in the central portion 21a of the actuator 20.

[0086] Moreover, such as Figure 5 As shown, the plunger 80 is disposed approximately in the internal space of the main body 31 in a region closer to the top than the region where the actuator 20 is disposed. The diameter of the region where the plunger 80 is disposed is smaller than the diameter of the region where the top portion 21b of the actuator 20 is disposed, and is a diameter that allows the plunger 80 to slide.

[0087] Furthermore, a portion of the container 70 is disposed approximately in the top-side region of the interior space of the main body 31. This region where the container 70 is disposed communicates with the region where the plunger 80 is disposed on its base end side, and its top side opens at the top surface of the attachment 30. An internal thread 36 for assembling the container 70 is formed on the inner wall of the region where the container 70 is disposed. The internal thread 36 is related to the following... Figure 6 , Figure 7 The external thread 74 of the container 70 shown is screwed in, thereby connecting the accessory 30 to the container 70.

[0088] Next, the plunger 80 will be described. The plunger 80 is a component that pressurizes the ejected fluid using energy received from the piston 40, and has a plunger rod 81 and a stop portion 82. The plunger rod 81 is formed, for example, of a resin material suitable for its pressurization, but is not limited thereto; for example, it may also be formed of the same material as that used in the attachment 30.

[0089] A stop portion 82, formed of an elastic component such as rubber, is fitted to the top end of the plunger rod 81. It should be noted that the specific material of the stop portion 82 can be, for example, butyl rubber or silicone rubber. Further examples include styrene-based elastomers, hydrogenated styrene-based elastomers, polyolefins mixed with polyethylene, polypropylene, polybutene, α-olefin copolymers, liquid paraffin, process oils, talc, casting powder, mica, and other powdered inorganic materials. Furthermore, various rubber materials (especially vulcanized rubber materials) such as polyvinyl chloride elastomers, olefin elastomers, polyester elastomers, polyamide elastomers, polyurethane elastomers, natural rubber, isoprene rubber, chloroprene rubber, nitrile rubber, and styrene-butadiene rubber, as well as mixtures thereof, can also be used as the material of the stop portion 82. Furthermore, the stop portion 82 slides within the container 70 while pressurizing the ejected liquid. Therefore, to ensure and adjust the sliding properties between the stop portion 82 and the inner wall surface 75a of the container 70's containing space 75, various substances can be used to coat or surface-process the surface of the stop portion 82 and the inner wall surface 75a of the container 70. As such coating agents, PTFE (polytetrafluoroethylene), silicone oil, diamond-like carbon, nanodiamonds, etc., can be used.

[0090] Figure 6 This is a cross-sectional view showing the approximate structure of container 70. Figure 7 This is an external view showing the general configuration of container 70. Container 70 is a component that contains the ejaculate liquid and defines the flow path for ejecting the ejaculate liquid, pressurized by plunger 80, to the target area. Container 70 is formed of a material that takes into account the pressurization of the plunger and the definition of the flow path. In this embodiment, container 70 is formed of resin material. It should be noted that container 70 is not limited to resin material, and may also be formed of, for example, the same material as that in Annex 30.

[0091] The container 70 is a space capable of containing the ejaculated liquid, having a receiving space 75 formed to allow the stop portion 82 of the plunger 80 to advance, and a flow path 76 connecting the receiving space 75 to an ejection port (ejection portion) 77 facing the outside of the container 70. Specifically, the container 70 has: a body 70a, which defines the receiving space 75 and has a cylindrical shape; and a nozzle portion 70c, which is connected to the top end side of the body 70a and defines the flow path 76. Moreover, the nozzle portion 70c is configured to have a top end portion 70c2 and a tapered portion 70c1, the top end portion 70c2 internally including a portion of the flow path 76 on the side of the ejection port 77, the tapered portion 70c1 connecting the top end portion 70c2 to the body 70a, and including a top end side outer surface 70c3 inclined relative to the central axis in the longitudinal direction of the attachment 30. Furthermore, an anti-misalignment member 50, described later, is embedded on the outer periphery of the top end portion 70c2.

[0092] In syringe assembly 10, such as Figure 5 As shown, the tip of the plunger 80 is embedded into the receiving space 75 of the container 70 in such a way that the stop 82 of the plunger 80 can slide in the receiving space 75 toward the nozzle 70c (tip side direction). With the plunger 80 embedded in the container 70 in this state, the space between the stop 82 of the plunger 80 and the container 70 becomes a storage space for the eluent, i.e., a space for sealing the eluent. In other words, when the plunger 80 is initially embedded in the receiving space 75 of the container 70, the tip surface of the stop 82 and the inner wall surface of the container 70, located closer to the tip surface of the stop 82, define the storage space. The flow path of the container 70 opens at the tip surface 73 of the nozzle 70c, forming an injection port 77. Therefore, when the plunger 80 slides within the receiving space 75, thereby pressurizing the eluent contained in the receiving space 75, the eluent is ejected from the injection port 77 through the flow path 76.

[0093] Furthermore, the inner diameter of the flow path 76 in the container 70 is made smaller than the inner diameter of the receiving space 75. With this configuration, the pressurized liquid is ejected from the ejection port 77 to the outside. Additionally, an external thread 74 for assembling the container 70 to the accessory 30 is formed on the outer periphery of the base end side. The external thread 74 engages with the internal thread 36 of the accessory 30.

[0094] The top end shape of the stop portion 82 in the plunger 80 is formed to approximately match the top end shape of the receiving space 75, which is defined by the inner wall surface 75a near the portion where the receiving space 75 connects to the flow path 76 (the innermost part of the receiving space 75). In this embodiment, both the top end shape of the stop portion 82 and the top end shape of the receiving space 75 are tapered shapes that narrow towards the top. Therefore, when the ejaculate is ejected, the gap between the stop portion 82 and the inner wall surface 75a of the container 70 is minimized as much as possible when the plunger 80 slides and reaches the innermost part of the receiving space 75, thus preventing ejaculate from remaining in the receiving space 75 and causing waste. However, the shape of the stop portion 82 is not limited to any particular shape, as long as the desired effect is achieved in the syringe 1 of this embodiment. Furthermore, the stop portion 82 is formed with an outer diameter slightly larger than the receiving space 75 of the container 70, so that when it is embedded in the receiving space 75 in a radially compressed state, it makes proper contact with the inner wall surface 75a in a manner that maintains an airtight seal with the container 70. It should be noted that, as long as a suitable ejaculate liquid can be ejected, the outer diameter of the stop portion 82 can also be approximately the same as the diameter of the receiving space 75, and is not formed to be larger than the diameter of the receiving space 75.

[0095] <Assembly of Syringe 1>

[0096] In assembling the syringe 1, the assembly of the syringe assembly 10 will be described first. With the stop 82 of the plunger 80 inserted into the innermost part of the receiving space 75 of the container 70, the outlet 77 of the container 70 is connected to the ejaculate fluid, and the plunger 80 is pulled back. The stop 82 is in close contact with the inner wall surface 75a of the receiving space 75, so a negative pressure is generated in the receiving space by its pull-back action, thereby filling the receiving space 75 with ejaculate fluid from the outlet 77. The pull-back amount of the plunger 80 at this time is set to such a level that when the container 70 is assembled with the accessory 30 in this state, the plunger 80 (plunger rod 81) exposed from the container 70 reaches the area for the piston 40 to be positioned in the internal space of the accessory 30.

[0097] When the container 70, with the receiving space 75 filled with the ejaculate liquid, is assembled to the attachment 30, the actuator 20 is further inserted into the attachment 30 from the base end side. The actuator 20 is inserted until the top surface of the piston 40, located at its top end 21b, reaches the base end surface of the plunger 80 within the attachment 30. At this point, the actuator 20 and attachment 30 are properly engaged by screwing the external thread 26 of the actuator 20's central portion 21a with the internal thread 32 of the attachment 30. The piston 40 assembled to the actuator 20 is then connected to the plunger 80. It should be noted that the connection between the piston 40 and the plunger 80 is not limited to simple contact; a fitting portion can also be provided at the top end of the piston 40 and the base end of the plunger 80 for engagement.

[0098] When the actuator 20 is assembled to the accessory 30, which is equipped with the container 70 and the plunger 80, as described above, the plunger 80 is pressed in such a way that it advances from the piston 40 toward the tip side, and within the container 70, the plunger 80 is positioned in a predetermined position (pre-operation position). At this time, in response to the pressing in of the plunger 80, excess ejaculate fluid in the container 70 is discharged from the ejection port 77, leaving a predetermined amount of ejaculate fluid in the container 70. It should be noted that the volume of the space for containing ejaculate fluid formed between the plunger 80, which is positioned in the pre-operation position, and the container 70 is determined to be the volume that ensures an appropriate amount of ejaculate fluid when the syringe 1 is operating. Therefore, when the syringe assembly 10 is assembled as described above, the amount of ejaculate fluid contained in the receiving space 75 of the container 70, i.e., the amount of ejaculate fluid to be ejected, is determined to be a predetermined amount.

[0099] The ignition lead 22b of the igniter 22 of the syringe assembly 10, configured in this way, is inserted into the socket 7 on the side of the housing 2, thereby loading it into the housing 2. Thus, a usable syringe 1 is prepared (see...). Figures 1-3 The user holds the syringe 1's housing 2 with one hand, causing the first switch 5 located at the rear of the housing 2 to slide continuously for a predetermined time, thus putting the syringe 1 into a standby state. Then, with the injection port 77 in contact with the target area, the user presses the second switch 6, thereby activating the igniter 22. This pressurizes the injection fluid via the piston 40 and plunger 80, injecting the injection fluid into the target area.

[0100] <Composition of Anti-Misalignment Components>

[0101] Next, the anti-misalignment component 50 located at the top of the syringe 1 will be described. Figure 8 This is a diagram showing the general structure of the anti-misalignment member 50, and is a side view of the anti-misalignment member 50 viewed from a direction orthogonal to the ejection direction of the syringe 1. Figure 9 yes Figure 8 sectional view, Figure 10 This is a diagram showing the anti-misalignment component 50 viewed from the top side. Figure 11 This is a diagram showing the anti-misalignment component 50 viewed from the base end side. Figure 12 This is a three-dimensional diagram showing the approximate structure of the anti-misalignment component 50.

[0102] The anti-misalignment component 50 includes: a base 51, which is arranged around an axis 59 along the ejection direction of the ejected liquid in a manner that surrounds the periphery of the ejection port 77; and a protrusion 52, which is provided on the target area side of the base 51.

[0103] The base 51 is an annular component, with the tip 70c2 of the nozzle portion 70c passing through its inner space 511, and the base 51 is externally fitted into the tip 70c2. That is, the anti-misalignment member 50 of this embodiment is assembled into the container 70 of the syringe 1. The base 51 of this embodiment is circular, but it is not limited to this; it may also be a shape such as a C-shape with a portion missing from the circle. It should be noted that the anti-misalignment member 50 is not limited to fitting; it may also be joined by other joining mechanisms such as screws or clips. Furthermore, the anti-misalignment member 50 of this embodiment can be detachably assembled, but it is not limited to this; it may also be fixedly assembled into the container 70 by bonding, welding, or other means. In addition, the assembly of the anti-misalignment member 50 is not limited to joining the separately formed anti-misalignment member 50 to the container 70; the anti-misalignment member 50 and the container 70 may also be integrally formed.

[0104] The base end side surface (base end surface) 513 of the substrate 51 is formed into a cone shape along the top end side outer surface (conical surface) 70c3 of the conical portion 70c1 of the nozzle portion 70c.

[0105] Multiple protrusions 521 of the concave-convex portion 52 are erected on the surface (base surface) 512 of the base 51 opposite to the target area. The multiple protrusions 521 are spaced apart from each other in the circumferential direction of the base surface 512. Thus, a concave portion 522 is formed between each protrusion 521. It should be noted that in this embodiment, the protrusions 521 are evenly spaced and are arranged rotationally symmetrically about axis 59.

[0106] exist Figure 8 , Figure 9 , Figure 12 In the figure, reference numeral 90 indicates the area of ​​the eyeball, which is the target of injection when using syringe 1. When syringe 1 is used, the injection port 77 is pressed against the eyeball, and the abutment surface 523 on the top side of the protrusion 521 of the anti-dislocation member 50 abuts against the eyeball. Therefore, the abutment surface 523 of each protrusion 521 is formed along a predetermined curved surface corresponding to the eyeball. Here, the predetermined curved surface is, for example, a sphere. By forming the abutment surface 523 along a spherical surface with an average diameter of the eyeball, the anti-dislocation member 50 can be used universally. Alternatively, it can be configured such that the abutment surface 523 is formed along a spherical surface with a diameter slightly larger than the average diameter of the eyeball, and when the anti-dislocation member 50 is pressed against the eyeball, in the case of an eyeball with a diameter less than the average diameter, the abutment surface 523 mainly abuts against the eyeball on the inner side, and in the case of an eyeball with a diameter greater than the average diameter, the abutment surface 523 mainly abuts against the eyeball on the outer side. It should be noted that the specified curved surface along which the contact surface 523 is located is not limited to a spherical surface. As long as the contact surface 523 of each protrusion 521 contacts the eyeball, it can also be a curved surface that deviates from the spherical surface. For example, the contact surface 523 can also be formed on a non-spherical surface with high curvature on the side (inner side) of the axis 59 and low curvature on the side (outer side) away from the axis 59 in the radial direction of the anti-misalignment member 50.

[0107] Figure 13 This is a schematic diagram showing the positional relationship between the contact surface 523 of the anti-misalignment component 50 and the injection port 77. For example... Figure 13 As shown, the contact surface 523 and the injection port 77 of the anti-misalignment member 50 are arranged along a predetermined curved surface 91. Therefore, when the injection port 77 of the syringe 1 is pressed against the eyeball, the contact surface 523 of each protrusion 521 abuts against the eyeball. It should be noted that the contact surface 523 and the injection port 77 are not limited to being strictly arranged on the predetermined curved surface 91. For example, the injection port 77 can be arranged at a position away from the predetermined curved surface 91 and at a predetermined distance from the base end, depending on the distance (predetermined distance) that the protrusion 521 is embedded in the surface of the eyeball. Thus, it is possible to configure the injection port 77 to abut against the surface of the eyeball when the injection port 77 of the syringe 1 is pressed against the eyeball, with each protrusion 521 embedded in the eyeball.

[0108] In this embodiment, when the injection port 77 is pressed against the eyeball while using the syringe 1, the anti-misalignment member 50 contacts the surface of the eyeball through the concave and convex portions 52. Compared with the case where only the injection port 77 is pressed against the surface of the eyeball, the frictional force increases, which can suppress the displacement of the syringe 1 relative to the target area of ​​the eyeball.

[0109] Furthermore, the protrusion 521 of the anti-misalignment member 50 abuts against the eyeball at a position radially away from the injection port 77, thus stabilizing the contact between the surface of the eyeball and the tip of the syringe and suppressing misalignment.

[0110] Furthermore, since the protrusion 521 of the anti-misalignment member 50 is arranged symmetrically, the force applied when the syringe 1 is pressed against the eyeball is evenly distributed around the injection port 77, thus effectively suppressing the deviation of the syringe 1.

[0111] <Second Implementation>

[0112] This embodiment differs from the first embodiment described above in the following structure: it includes a container holder 71 for holding the container 70, and an anti-misalignment member 50A is fitted onto the container holder (holding part) 71. It should be noted that the other components are the same as in the first embodiment described above; therefore, identical reference numerals are used for the same elements, and further description is omitted.

[0113] Figure 14 This is a diagram showing the schematic configuration of the anti-misalignment member 50A and the container 70A according to the second embodiment. Figure 15 This is a diagram used to illustrate the positional relationship between the container 70A and the container holder 71 in the second embodiment.

[0114] The container 70A of this embodiment does not have an external thread that engages with the internal thread 36 formed on the inner wall of the top side of the attachment 30. Therefore, the assembly of the container 70A with respect to the attachment 30 is achieved by the container holder 71. The container holder 71 has: a body 71a that defines the space for the inner container 70A; a threaded portion 71b that is connected to the base end of the body 71a and has an external thread that engages with the internal thread 36; and a contact portion 71c that is connected to the top side of the body 71a and has an inner surface 71c1 that contacts the outer surface 70c3 of the top side of the container 70A (see reference). Figure 15 In addition, such as Figure 15 As shown, the contact portion 71c is provided with an opening 71c2 that allows the top portion 70c2 of the container 70A to pass through.

[0115] An anti-misalignment member 50A is provided on the top surface 71c3 of the container holder 71. The anti-misalignment member 50A includes: a base 51, which is arranged around an axis 59 along the ejection direction of the ejected liquid, surrounding the opening 71c2; and a protrusion / recess 52, which is provided on the target area side of the base 51. The base end side surface (base end surface) 514 of the base 51 is attached to the top surface 71c3 of the container holder 71 by bonding, welding, or the like. It should be noted that the anti-misalignment member 50 in this embodiment is fixedly attached to the container holder 71, but it can also be detachably attached to the container holder 71 via screws or fittings. Furthermore, the assembly of the anti-misalignment member 50 is not limited to joining the separately formed anti-misalignment member 50 to the container holder 71, but the anti-misalignment member 50 can also be integrally formed with the container holder 71.

[0116] The container 70A is accommodated in the container holder 71 with the top portion 70c2 passing through the opening 71c2. At this time, the target substance is injected into the container 70A to fill the accommodating space 75, and the plunger 80 is also installed. In this accommodated state, the outer surface 70c3 of the top side of the container 70A contacts the inner surface 71c1 of the container holder 71 on the top side, and the base end portion 70b of the container 70A contacts the threaded portion 71b of the container holder 71 on the base end side. Then, while the container holder 71 is in the state of accommodating the container 70A, the external thread formed on the threaded portion 71b of the container holder 71 is screwed into the internal thread portion 36 of the attachment 30 until the end face of the base end portion 70b of the container 70A contacts the end face 35a of the third region 35 of the attachment 30. As a result, using the fastening force achieved through this screw engagement, the container 70A is assembled to the attachment 30 in the following state: the outer surface 70c3 of the top side of the container 70A is pressed from the top side toward the base side by the container holder 71, that is, pressed in the opposite direction to the movement direction of the plunger 80. Furthermore, at this time, the plunger 80 is positioned across the receiving space 75 within the container 70A and the area within the attachment 30 that generally accommodates the plunger 80.

[0117] The process of assembling the syringe assembly 10 by attaching the actuator 20 to the accessory 30 in this state and the process of assembling the syringe 1 are the same as those described in the first embodiment.

[0118] In this embodiment, the syringe 1 has an anti-displacement member 50A at the top of the container holder 71. When the syringe 1 is used and the nozzle 77 is pressed against the eyeball, the concave and convex portions 52 of the anti-displacement member 50A contact the surface of the eyeball, thereby suppressing the displacement of the syringe 1.

[0119] <Third Implementation Method>

[0120] The difference between this embodiment and the first embodiment described above lies in the configuration of the concave and convex portions 52B. It should be noted that the other configurations are the same as in the first embodiment described above; therefore, identical reference numerals are used for the same elements, and further descriptions are omitted.

[0121] Figure 16 This is a cross-sectional view showing the schematic configuration of the anti-misalignment member 50B and the container 70 according to the third embodiment. Figure 17 This is a diagram showing the anti-misalignment component 50B viewed from the top side. (See diagram below.) Figure 16 , Figure 17 As shown, the anti-misalignment member 50B of this embodiment includes: a base 51 surrounding the injection port 77; and a concave-convex portion 52B provided on the target area side of the base 51.

[0122] Multiple protrusions 521B are provided concentrically on the surface (base surface) 512 of the base 51 opposite the target area. Each protrusion 521B is spaced apart from the others radially on the base surface 512. Thus, a recess 522B is formed between each protrusion 521B. It should be noted that in this embodiment, the protrusions 521B are evenly spaced, and each protrusion 521B is rotationally symmetrical about axis 59. Each protrusion 521B appears circular when viewed from the top side, but it can also be divided into multiple parts, with a portion of the circle missing.

[0123] In this embodiment, when the nozzle 77 of the syringe 1 is pressed against the eyeball, the uneven portion 52B of the anti-misalignment member 50B contacts the surface of the eyeball, and the frictional force increases compared to the case where only the nozzle 77 is pressed against the surface of the eyeball, thus suppressing the displacement of the syringe 1 relative to the target area of ​​the eyeball.

[0124] <Fourth Implementation>

[0125] This embodiment differs from the first embodiment described above in the following configuration: the syringe 1C is not a needleless syringe, but a syringe with a needle, and an anti-misalignment component 50C is fitted to its needle hub. It should be noted that other configurations are the same as in the first embodiment described above; therefore, identical reference numerals are used for the same elements, and further description is omitted.

[0126] Figure 18 This is a schematic diagram of the syringe 1C according to the fourth embodiment. Figure 19 This is a diagram showing the top side of the anti-misalignment member 50C according to the fourth embodiment. Figure 20 This is a diagram showing the base end side of the anti-misalignment member 50C according to the fourth embodiment. (See diagram below.) Figure 18 As shown, syringe 1C has a syringe barrel 78, a syringe rod 85, and a syringe needle 60.

[0127] The syringe 78 has a generally cylindrical outer body 781 with a nozzle 782 at its top. The nozzle 782 is formed into a generally cylindrical shape with a diameter smaller than that of the outer body 781. The outer body 781 and the nozzle 782 are connected by communicating internal space. That is, the top side of the internal space in the outer body 781 is closed except for the part communicating with the internal space of the nozzle 782. A flange (finger hook portion) 783 is provided at the rear end of the outer body 781, extending radially from the outer circumference of the cylinder.

[0128] The syringe 78 is made of, for example, transparent plastic. The material of the first outer cylinder 11 is not particularly limited; in addition to plastic, it can also be metal, glass, or ceramic.

[0129] The injection rod 85 has a rod-shaped rod portion 851, a washer 852 at the top end of the rod portion 851, and a flange 853 at the rear end of the rod portion 851. The top end of the injection rod 85 is inserted into the internal space from the rear end of the outer cylinder body 781. The washer 852 of the injection rod 85 inserted into the internal space of the outer cylinder body 781 contacts the inner circumferential surface of the outer cylinder body 781, and can move along the inner circumferential surface towards the top end or the rear end in this state (forward and backward movement). That is, the injection rod 85 is held in a state in which the washer 852 at the top end contacts the inner circumferential surface of the outer cylinder body 781, thus maintaining the airtightness of the internal space, and can move forward and backward.

[0130] The injection needle 60 includes a needle tube (ejection portion) 61 and a needle seat 62, which are connected by an internal space connection. A recess is provided at the base end of the needle seat 62 for engaging with the nozzle 782 of the syringe 78. When the nozzle 782 of the syringe 78 is inserted into the recess of the needle seat 62 and the injection needle 60 is assembled into the syringe 78, the internal space of the injection needle 60 is in communication with the internal space of the syringe 78.

[0131] Regarding the syringe 1C, which is assembled from the syringe barrel 78, the syringe rod 85, and the syringe needle 60, when the tip of the syringe needle 60 is immersed in an ejaculate liquid corresponding to the target substance, and the syringe rod 85 moves relative to the syringe barrel 78 towards the base, the ejaculate liquid is drawn in and contained within the syringe barrel 78. Furthermore, regarding the syringe 1C, when the ejaculate liquid is contained within the syringe barrel 78, and the tip of the syringe needle 60 punctures the target area, and the syringe rod 85 moves relative to the syringe barrel 78 towards the tip, the ejaculate liquid is expelled and injected into the target area.

[0132] The anti-misalignment member 50C of this embodiment includes: a base 51, which is arranged around an axis 59 along the injection direction of the injection liquid in a manner that surrounds the injection needle 60; and a concave-convex portion 52, which is provided on the target area side of the base 51.

[0133] The base 51 is an annular component, through which the needle tube 61 of the injection needle 60 passes. The base 51 is externally fitted onto the top end of the needle holder 62. It should be noted that the anti-misalignment component 50C of this embodiment is detachably assembled through the fitting of the base 51 and the needle holder 62, but it is not limited to this; it can also be fixed to the needle holder 62 by bonding, welding, or other methods. Furthermore, the anti-misalignment component 50C can also be integrally formed with the needle holder 62.

[0134] The base end side surface (base end surface) 513 of the base 51 is formed in a conical shape along the outer surface (conical surface) of the top end side of the needle seat 62.

[0135] Multiple protrusions 521 of the concave-convex portion 52 are erected on the surface (base surface) 512 of the base 51 opposite to the target area. It should be noted that the structure and function of the concave-convex portion 52 are the same as those in the aforementioned embodiment.

[0136] In this embodiment, the syringe 1C is used by inserting the tip of the injection needle 60 into the target area until the anti-displacement member 50C comes into contact with the symmetrical area. In this state, the injection rod 85 is moved relative to the syringe barrel 78 towards the tip, thereby injecting the ejaculate into the target area. Thus, in this embodiment, when the ejaculate is injected into the target area, the protrusion 52 of the anti-displacement member 50C contacts the surface of the symmetrical area (e.g., the surface of the eyeball), thereby suppressing the displacement of the syringe 1C relative to the target area.

[0137] <Fifth Implementation>

[0138] This embodiment differs from the aforementioned fourth embodiment in the following configuration: the injection needle 60D includes a sleeve 63 and a protective cover 64, and the anti-misalignment component 50D is assembled into the sleeve 63. It should be noted that other configurations are the same as in the aforementioned fourth embodiment; therefore, identical reference numerals are used for the same elements, and further description is omitted.

[0139] Figure 21 This is a schematic diagram of the syringe 1D according to the fifth embodiment. Figure 22 This is a cross-sectional view showing the tip side of the syringe 1D. In addition to the needle tube 61 and needle seat 62, the syringe 1D of this embodiment also includes a sleeve 63, a protective cover 64, and a spring 65.

[0140] The sleeve 63 is a generally cylindrical member that houses the base end of the needle hub 62 and the needle tube 61. The sleeve 63 houses at least the base end of the shield 64 and holds the shield 64 movable forward and backward along the ejection direction of the syringe 1D. The shield 64 is a generally cylindrical member arranged radially around the needle tube 61. A hole 641 for the needle tube 61 to pass through is provided on the top end side of the shield 64. A spring 65 is provided on the base end side of the shield 64, and the shield 64 is forceped towards the top end side. Therefore, when the shield 64 is not subjected to external force (not in use), the shield 64 covers the top end portion of the needle tube 61. Furthermore, when using the syringe 1D, if the shield 64 is pressed towards the base end side, the shield 64 compresses the spring 65 and moves towards the base end side, exposing the top end portion of the needle tube 61.

[0141] The sleeve 63 is connected to the needle holder 62, which is externally fitted into the opening 782 of the syringe 78, thereby assembling the injection needle 60D, including the sleeve 63, into the syringe 78. At this time, even if the syringe 78 is filled with the injection fluid, the injection fluid can be filled into the syringe 78 through the injection needle 60D after it is assembled.

[0142] The anti-misalignment member 50D of this embodiment includes: a base 51, which is arranged around an axis 59 along the ejection direction of the ejected liquid in a manner that surrounds the needle tube 61 and the shield 64; and a concave-convex portion 52, which is provided on the target area side of the base 51.

[0143] The base 51 is an annular component, allowing the needle tube 61 of the injection needle 60D and the protective cover 64 to pass through its inner space 511D. The base 51 is fitted into the top end of the sleeve 63. It should be noted that the anti-dislocation component 50D of this embodiment is detachably assembled through the fitting of the base 51 and the sleeve 63, but it is not limited to this; it can also be fixed to the sleeve 63 by bonding, welding, or other methods. Furthermore, the anti-dislocation component 50D can also be integrally formed with the sleeve 63.

[0144] Multiple protrusions 521 of the concave-convex portion 52 are erected on the surface (base surface) 512 of the base 51 opposite to the target area. It should be noted that the structure and function of the concave-convex portion 52 are the same as in the embodiment described above.

[0145] When in use, the tip of syringe 1D is pressed against the target area. At this time, the shield 64 is located at the tip and covers the needle tube 61 until syringe 1D contacts the target area. When the shield 64 reaches the target area, the shield 64 abuts against the surface of the target area and stops advancing, but the part of syringe 1D other than the shield 64 advances relative to the shield 64 while compressing the spring 65. Then, syringe 1D is inserted until the needle tube 61 pierces the target area and the anti-displacement member 50D abuts against the symmetrical area. In this state, the injection rod 85 moves towards the tip side relative to the syringe barrel 78, thereby injecting the eluent into the target area. In this way, in this embodiment, when the eluent is injected into the target area, the concave and convex portions 52 of the anti-displacement member 50D contact the surface of the symmetrical area (e.g., the surface of the eyeball), thereby suppressing the displacement of syringe 1D relative to the target area.

[0146] The above describes the embodiments of the anti-misalignment component 50 disclosed herein, but the various solutions disclosed in this specification can also be combined with any other features disclosed in this specification.

[0147] Explanation of reference numerals in the attached figures

[0148] 1: Syringe;

[0149] 2: Shell;

[0150] 3: Power cable;

[0151] 4: Connector;

[0152] 7: Socket;

[0153] 10: Syringe assembly;

[0154] 20: Actuator;

[0155] 20a: Combustion chamber;

[0156] 21: Main body;

[0157] 22: Igniter;

[0158] 26: External thread section;

[0159] 27: Opening;

[0160] 30: Attachments;

[0161] 31: Main body;

[0162] 32: Internal thread section;

[0163] 35: Third Region;

[0164] 36: Internal thread section;

[0165] 40: Piston;

[0166] 50: Anti-misalignment component;

[0167] 50A: Anti-misalignment component;

[0168] 51: Matrix;

[0169] 52: Uneven or concave parts;

[0170] 59: Axis;

[0171] 70: Container;

[0172] 70A: Container;

[0173] 70c: Nozzle section;

[0174] 70c1: Conical part;

[0175] 70c2: Top part;

[0176] 70c3: Top side outer surface;

[0177] 71: Container holder;

[0178] 73: Top face;

[0179] 74: External thread section;

[0180] 75: Accommodation space;

[0181] 75a: Inner wall surface;

[0182] 76: Flow path;

[0183] 77: Ejection port;

[0184] 80: Plunger;

[0185] 81: Plunger rod;

[0186] 82: Stop part;

[0187] 91: Define the curved surface;

[0188] 511: Inner space;

[0189] 512: Base surface;

[0190] 521: convex part;

[0191] 522: concave part;

[0192] 523: Contact surface.

Claims

1. An anti-misalignment component for suppressing the displacement of a syringe from a target region of the eyeball, the syringe ejecting a target substance from an ejection portion toward the target region, the anti-misalignment component comprising: The matrix is ​​arranged around an axis along the ejection direction of the injected target material, in a manner that surrounds the periphery of the ejection portion; and The protrusions and recesses are provided on the object region side of the substrate.

2. The anti-misalignment component according to claim 1, wherein, The syringe is a needleless syringe that injects the target substance into the target area by ejecting the target substance from the ejection port, which serves as the ejection part, without passing through an injection needle.

3. The anti-misalignment component according to claim 2, wherein, The needle-free injector includes a receiving portion having a receiving space for receiving the injected target substance, and an injection port for ejecting the injected target substance into the target area. The substrate is assembled into the receiving portion of the needle-free injector.

4. The anti-misalignment component according to claim 2, wherein, The needle-free injector comprises: a receiving portion having a receiving space for receiving the target substance and an ejection port for ejecting the target substance into the target area; and a retaining portion for retaining the receiving portion. The substrate is fitted to the retaining part of the needleless injector.

5. The anti-misalignment component according to claim 1, wherein, The ejection portion of the syringe is equipped with an injection needle. The substrate is positioned to surround the injection needle around the axis.

6. The anti-misalignment component according to any one of claims 2 to 5, wherein, The concave and convex portion has multiple protrusions around the axis, and the contact surface of each protrusion that abuts against the eyeball is formed along a predetermined curved surface corresponding to the eyeball.

7. A syringe that ejects a target substance from an ejection portion into a target region of the eyeball, the syringe comprising: The receiving portion has a receiving space for receiving the injected target substance, and has an ejection portion for ejecting the injected target substance into the target area; and An anti-misalignment component is used to suppress the displacement of the syringe relative to the target area. The anti-misalignment component includes: The matrix is ​​arranged around an axis along the ejection direction of the injected target material, in a manner that surrounds the periphery of the ejection portion; and The concave and convex portions are provided on the surface of the substrate opposite to the object region.

8. The syringe according to claim 7, wherein, The syringe is a needleless syringe that injects the target substance into the target area by ejecting the target substance from the ejection port, which serves as the ejection part, without passing through an injection needle.

9. The syringe according to claim 8, wherein, The substrate is assembled into the receiving portion of the needle-free injector.

10. The syringe according to claim 8, wherein, The syringe also includes a retaining part for holding the receiving portion. The substrate is fitted to the retaining part of the needleless injector.

11. The syringe according to claim 7, wherein, The ejection section is equipped with an injection needle. The substrate is positioned to surround the injection needle around the axis.

12. The syringe according to any one of claims 7 to 11, wherein, The concave and convex portion has multiple protrusions around the axis, and the contact surface of each protrusion that abuts against the eyeball is formed along a predetermined curved surface corresponding to the eyeball.

Images